These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28975182)

  • 21. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment.
    Maecke HR; Reubi JC
    J Nucl Med; 2011 Jun; 52(6):841-4. PubMed ID: 21571797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A theoretical radiobiological assessment of the influence of radionuclide half-life on tumor response in targeted radiotherapy when a constant kidney toxicity is maintained.
    Abou-Jaoudé W; Dale R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):308-21. PubMed ID: 15285877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in radionuclide therapy.
    Srivastava S; Dadachova E
    Semin Nucl Med; 2001 Oct; 31(4):330-41. PubMed ID: 11710775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. β-radiating radionuclides in cancer treatment, novel insight into promising approach.
    Asadian S; Mirzaei H; Kalantari BA; Davarpanah MR; Mohamadi M; Shpichka A; Nasehi L; Es HA; Timashev P; Najimi M; Gheibi N; Hassan M; Vosough M
    Pharmacol Res; 2020 Oct; 160():105070. PubMed ID: 32659429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour therapy with radionuclides: assessment of progress and problems.
    Carlsson J; Forssell Aronsson E; Hietala SO; Stigbrand T; Tennvall J
    Radiother Oncol; 2003 Feb; 66(2):107-17. PubMed ID: 12648782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: experimental models and clinical applications.
    Bodei L; Kassis AI; Adelstein SJ; Mariani G
    Cancer Biother Radiopharm; 2003 Dec; 18(6):861-77. PubMed ID: 14969599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials in molecular radiotherapy-Tribulations and Triumphs Report of the NCRI CTRad meeting held at the Lift Islington, 8 June 2018.
    Falzone N; Gregory R; Aldridge M; Terry SY; Flux G
    Br J Radiol; 2019 Aug; 92(1100):20190117. PubMed ID: 30982344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor imaging and therapy.
    Scott AM; Larson SM
    Radiol Clin North Am; 1993 Jul; 31(4):859-79. PubMed ID: 8337372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Applications of particle accelerators in medicine.
    Silari M
    Radiat Prot Dosimetry; 2011 Jul; 146(4):440-50. PubMed ID: 21676897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radionuclide therapy in oncology: repeated administrations of high dose rate radiopharmaceuticals.
    Palmedo H; Bucerius J
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1556. PubMed ID: 15372210
    [No Abstract]   [Full Text] [Related]  

  • 31. Systemic targeted radionuclide therapy: potential new areas.
    Wong JY
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S74-82. PubMed ID: 16979445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The management of painful bone metastases with an emphasis on radionuclide therapy.
    Hillegonds DJ; Franklin S; Shelton DK; Vijayakumar S; Vijayakumar V
    J Natl Med Assoc; 2007 Jul; 99(7):785-94. PubMed ID: 17668645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Basic immunology of antibody targeted radiotherapy.
    Wong JY
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S8-14. PubMed ID: 16979446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endoradiotherapy in cancer treatment--basic concepts and future trends.
    Zoller F; Eisenhut M; Haberkorn U; Mier W
    Eur J Pharmacol; 2009 Dec; 625(1-3):55-62. PubMed ID: 19836381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radionuclide therapy of bone metastases: prospects for enhancement of therapeutic efficacy.
    Mertens WC
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):49-55. PubMed ID: 7684866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dosimetry in Peptide radionuclide receptor therapy: a review.
    Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
    J Nucl Med; 2006 Sep; 47(9):1467-75. PubMed ID: 16954555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extremely high-frequency therapy in oncology.
    Teppone M; Avakyan R
    J Altern Complement Med; 2010 Nov; 16(11):1211-6. PubMed ID: 20973733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Which radionuclides will nuclear oncology need tomorrow?
    Barbet J; Chatal JF; Gauché F; Martino J
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):627-30. PubMed ID: 16741760
    [No Abstract]   [Full Text] [Related]  

  • 39. Peptide receptor radionuclide therapy: an overview.
    Dash A; Chakraborty S; Pillai MR; Knapp FF
    Cancer Biother Radiopharm; 2015 Mar; 30(2):47-71. PubMed ID: 25710506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical applications of newer radionuclide therapies.
    Brans B; Linden O; Giammarile F; Tennvall J; Punt C
    Eur J Cancer; 2006 May; 42(8):994-1003. PubMed ID: 16564689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.